Jin Medical International Ltd. (ZJYL) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↑
32.66
↓-63% vs avg
5yr avg: 89.19
30Y Low54.0·High54.0
P/FCF
N/A
—
5yr avg: 56.75
30Y Low56.7·High56.7
P/B Ratio
↓
0.64
↓-92% vs avg
5yr avg: 8.27
30Y Low3.0·High14.7
ROE
↓
4.1%
↑-72% vs avg
5yr avg: 14.5%
30Y Low4%·High41%
Debt/EBITDA
↑
20.27
↑+148% vs avg
5yr avg: 8.17
30Y Low0.2·High20.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZJYL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Jin Medical International Ltd. trades at 16.2x earnings, 80% below its 5-year average of 83.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 27%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $88M | $421M | $170M | — | — | — | — | — |
| Enterprise Value | $30M | $100M | $424M | $167M | — | — | — | — | — |
| P/E Ratio → | 16.20 | 75.33 | 114.47 | 59.09 | — | — | — | — | — |
| P/S Ratio | 0.92 | 4.28 | 17.91 | 8.57 | — | — | — | — | — |
| P/B Ratio | 0.64 | 2.99 | 14.74 | 7.08 | — | — | — | — | — |
| P/FCF | — | — | — | 56.75 | — | — | — | — | — |
| P/OCF | 6.55 | 30.46 | — | 54.66 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZJYL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Jin Medical International Ltd.'s enterprise value stands at 32.7x EBITDA, 63% below its 5-year average of 89.2x. The Healthcare sector median is 14.2x, placing the stock at a 130% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.83 | 18.06 | 8.42 | — | — | — | — | — |
| EV / EBITDA | 32.66 | 107.09 | 106.50 | 53.99 | — | — | — | — | — |
| EV / EBIT | 50.10 | 164.26 | 116.63 | 58.24 | — | — | — | — | — |
| EV / FCF | — | — | — | 55.80 | — | — | — | — | — |
ZJYL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Jin Medical International Ltd. earns an operating margin of 2.9%. Operating margins have compressed from 14.5% to 2.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 4.1% is modest. ROIC of 1.2% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.2% | 29.2% | 40.4% | 34.2% | 32.3% | 30.6% | 34.0% | 36.9% | 36.6% |
| Operating Margin | 2.9% | 2.9% | 15.5% | 14.5% | 11.1% | 12.7% | 14.5% | 21.6% | 20.2% |
| Net Profit Margin | 5.8% | 5.8% | 15.6% | 14.5% | 14.1% | 12.7% | 13.6% | 17.9% | 17.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.1% | 4.1% | 14.0% | 14.7% | 18.5% | 21.2% | 20.5% | 37.0% | 40.9% |
| ROA | 2.4% | 2.4% | 9.3% | 10.7% | 12.6% | 12.3% | 10.7% | 18.7% | 19.7% |
| ROIC | 1.2% | 1.2% | 10.3% | 13.6% | 15.4% | 17.8% | 15.1% | 32.2% | 35.8% |
| ROCE | 2.1% | 2.1% | 13.8% | 14.6% | 14.6% | 21.2% | 21.9% | 44.7% | 47.0% |
ZJYL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Jin Medical International Ltd. carries a Debt/EBITDA ratio of 20.3x, which is highly leveraged (529% above the sector average of 3.2x). Net debt stands at $11M ($19M total debt minus $7M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.64 | 0.64 | 0.41 | 0.17 | — | — | 0.25 | 0.27 | 0.08 |
| Debt / EBITDA | 20.27 | 20.27 | 2.91 | 1.33 | — | — | 0.99 | 0.60 | 0.16 |
| Net Debt / Equity | — | 0.39 | 0.12 | -0.12 | -0.31 | -0.26 | 0.09 | 0.09 | -0.02 |
| Net Debt / EBITDA | 12.27 | 12.27 | 0.87 | -0.91 | -1.93 | -1.24 | 0.37 | 0.20 | -0.03 |
| Debt / FCF | — | — | — | -0.94 | -3.11 | -0.63 | 0.42 | — | — |
| Interest Coverage | — | — | — | — | — | 304.45 | 21.93 | 192.76 | — |
ZJYL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.86x means Jin Medical International Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.49x to 1.86x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | 1.86 | 2.50 | 3.49 | 3.31 | 2.47 | 1.81 | 1.83 | 1.61 |
| Quick Ratio | 1.65 | 1.65 | 2.08 | 2.83 | 2.11 | 1.57 | 1.09 | 1.24 | 0.99 |
| Cash Ratio | 1.25 | 1.25 | 1.56 | 1.87 | 1.24 | 0.73 | 0.28 | 0.35 | 0.25 |
| Asset Turnover | — | 0.39 | 0.51 | 0.60 | 0.92 | 0.95 | 0.78 | 1.00 | 1.12 |
| Inventory Turnover | 2.97 | 2.97 | 1.97 | 2.23 | 1.89 | 2.05 | 1.47 | 2.24 | 2.19 |
| Days Sales Outstanding | — | 120.02 | 136.29 | 156.53 | 80.87 | 105.11 | 177.19 | 154.59 | 110.70 |
ZJYL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Jin Medical International Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 6.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.2% | 1.3% | 0.9% | 1.7% | — | — | — | — | — |
| FCF Yield | — | — | — | 1.8% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $8M | $8M | $7M | $7M | $13M | $20M | $20M | $20M |
Peer Comparison
Compare ZJYL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZJYLYou | $19M | 16.2 | 32.7 | — | 29.2% | 2.9% | 4.1% | 1.2% | 20.3 |
 MPWR | $76B | 120.6 | 95.5 | 113.4 | 55.2% | 26.1% | 18.4% | 22.2% | 0.0 |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 LFUS | $12B | -168.7 | 92.3 | 33.8 | 38.0% | 1.6% | -3.0% | 1.0% | 6.8 |
 GKOS | $8B | -40.0 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 INVA | $2B | 6.9 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 OSUR | $299M | -4.4 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 LMAT | $2B | 35.2 | 27.8 | 27.1 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 ATRC | $1B | -118.5 | 79.6 | 29.8 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SYK | $117B | 36.3 | 21.0 | 27.2 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ZJYL — Frequently Asked Questions
Quick answers to the most common questions about buying ZJYL stock.
What is Jin Medical International Ltd.'s P/E ratio?
Jin Medical International Ltd.'s current P/E ratio is 16.2x. The historical average is 83.0x.
What is Jin Medical International Ltd.'s EV/EBITDA?
Jin Medical International Ltd.'s current EV/EBITDA is 32.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 54.0x.
What is Jin Medical International Ltd.'s ROE?
Jin Medical International Ltd.'s return on equity (ROE) is 4.1%. The historical average is 21.4%.
Is ZJYL stock overvalued?
Based on historical data, Jin Medical International Ltd. is trading at a P/E of 16.2x. Compare with industry peers and growth rates for a complete picture.
What are Jin Medical International Ltd.'s profit margins?
Jin Medical International Ltd. has 29.2% gross margin and 2.9% operating margin.
How much debt does Jin Medical International Ltd. have?
Jin Medical International Ltd.'s Debt/EBITDA ratio is 20.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.